Nanbu A, Kumamoto Y, Takagi Y, Maruta H
Department of Urology, Sapporo Medical College.
Hinyokika Kiyo. 1989 Oct;35(10):1715-20.
Two boys and one girl with idiopathic precocious puberty were treated with medroxyprogesterone acetate (MPA) for 2 years and 2 months to 9 years and 5 months, and its efficiency was evaluated. Treatment with MPA suppressed the gonadotropin levels, the signs and symptoms of patients with precocious puberty, and also had a suppressive effect on bone-age advance, so these patients showed almost normal growth in height. There has been controversy about the age when treatment for idiopathic precocious puberty should be finished. Our data suggested that the treatment should be stopped at 11-13 years when patients reach the age of puberty.
对两名患有特发性性早熟的男孩和一名患有特发性性早熟的女孩使用醋酸甲羟孕酮（MPA）进行了2年2个月至9年5个月的治疗，并对其疗效进行了评估。MPA治疗可抑制促性腺激素水平、性早熟患者的体征和症状，并且对骨龄进展也有抑制作用，因此这些患者的身高增长几乎正常。关于特发性性早熟的治疗应在何时结束存在争议。我们的数据表明，当患者达到青春期年龄时，应在11至13岁停止治疗。
